Evolution of postmenopausal hormone therapy between 2002 and 2009

Menopause

Volumn 19, Issue 6, 2012, Pages 610-615

  Ettinger, Bruce ^a   Wang, Sharon M ^b   Leslie, R Scott ^b   Patel, Bimal V ^b   Boulware, Michael J ^c   Mann, Mark E ^c   McBride, Michael ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MedImpact Healthcare Systems Inc   (United States)

^c Upsher Smith Laboratories Inc   (United States)

Author keywords

Hormone therapy; Prescribing trends; Women's Health Initiative

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL; ESTRADIOL ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL PLUS NORGESTIMATE; ESTRATEST; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; PIPERAZINE ESTRONE SULFATE;

ARTICLE; DRUG FORMULATION; DRUG MEGADOSE; FEMALE; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; PRESCRIPTION; RETROSPECTIVE STUDY; SPECIALIZATION;

ADMINISTRATION, CUTANEOUS; AGED; CONTROLLED CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INSURANCE CLAIM REPORTING; INSURANCE, PHARMACEUTICAL SERVICES; MENOPAUSE; MIDDLE AGED; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; WOMEN'S HEALTH;

EID: 84862126774     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31823a3e5d     Document Type: Article

References (31)

1. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-553.
2. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104: 1042-1050.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
4. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
5. American College of Obstetricians and Gynecologists. Vasomotor symptoms. Obstet Gynecol 2004;104:S106-S117.
6. The North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33.
7. Naftolin F, Schneider HP, Sturdee DW. Guidelines for hormone treatment of women in the menopausal transition and beyond. Maturitas 2005;51:15-20.
8. Hartsfield CL, Connelly MT, Newton KM, Andrade SE, Wei F, Buist DS. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response. J Natl Cancer Inst Monogr 2005;35:113-115.
9. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-188.
10. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
11. Hillman JJ, Zuckerman IH, Lee E. The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program. J Womens Health 2004;13:986-992.
12. Mishra G, Kok H, Ecob R, Cooper R, Hardy R, Kuh D. Cessation of hormone replacement therapy after reports of adverse findings from randomized controlled trials: evidence from a British Birth Cohort. Am J Public Health 2006;96:1219-1225.
13. Newton KM, Buist DS, Miglioretti DL, et al. The impact of comorbidities on hormone use. After the 2000 release of the Women's Health Initiative. J Gen Intern Med 2005;20:350-356.
14. Haas JS, Geller B, Miglioretti DL, et al. Changes in newspaper coverage about hormone therapy with the release of new medical evidence. J Gen Intern Med 2006;21:304-309.
15. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.
16. Wei F, Miglioretti DL, Connelly MT, et al. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. J Natl Cancer Inst Monogr 2005;35: 106-112.
17. Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 2005;14:171-176.
18. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292:1983-1988.
19. Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011;96:255-264.
20. US Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005;142: 855-860.
21. The North American Menopause Society. Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007;14:168-182.
22. Carroll N. A review of transdermal nonpatch estrogen therapy for the management of menopausal symptoms. J Womens Health (Larchmt) 2010;19:47-55.
23. Parente L, Uyehara C, Larsen W, Whitcomb B, Farley J. Long-term impact of the Women's Health Initiative on HRT. Arch Gynecol Obstet 2008;277:219-224.
24. Spencer C, Crook D, Ross D, Cooper A, Whitehead M, Stevenson J. A randomised comparison of the effects of oral versus transdermal 17Aoestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. Br J Obstet Gynaecol 1999;106:948-953.
25. Sendag F, Karadadas N, Ozsener S, Bilgin O. Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women. Arch Gynecol Obstet 2002;266:38-43.
26. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol 2006;47:1741-1753.
27. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-1231.
28. Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337:a386.
29. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005;293:330-339.
30. AACE Menopause Guidelines Revisions Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 2006;12: 315-337.
31. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005;118:74-78.